OBJECTIVE: To examine the relationship between cognitive impairment and functional limitations and disability in persons with rheumatoid arthritis (RA). METHODS: Individuals from a longitudinal cohort study of RA participated in study visits that included physical, psychosocial, and biological metrics. Cognitive function was assessed using a battery of 12 standardized neuropsychological measures yielding 16 indices covering a range of cognitive domains. On each test, subjects were classified as "impaired" if they performed 1 SD below age-based population norms. Total cognitive function scores were calculated by summing the number of tests on which individuals were classified as "impaired" (higher scores = greater impairment). Performance-based and self-reported functional limitations were assessed with the Short Physical Performance Battery (SPPB) and the Health Assessment Questionnaire (HAQ), respectively. Self-reported disability was measured with the Valued Life Activities (VLA) scale. Multiple regression analyses controlling for sex, race, education, cardiovascular comorbidity, disease duration, disease severity, and depression were conducted to identify whether cognitive impairment was independently associated with physical function difficulties. RESULTS: There were 122 subjects with mean (SD) age of 58.4 (± 10.8) years; 62% were female and 80% were white. In multivariate regression models, total cognitive function score was significantly associated with greater functional limitations (SPPB: β = -0.24, p = 0.014; HAQ: β = 0.24, p = 0.003) but not with disability (VLA: β = 0.10, p = 0.207). CONCLUSION: Cognitive impairment was significantly associated with greater functional limitations in patients with RA, suggesting that cognitive impairment may play a role in poor functional status in persons with RA.
OBJECTIVE: To examine the relationship between cognitive impairment and functional limitations and disability in persons with rheumatoid arthritis (RA). METHODS: Individuals from a longitudinal cohort study of RA participated in study visits that included physical, psychosocial, and biological metrics. Cognitive function was assessed using a battery of 12 standardized neuropsychological measures yielding 16 indices covering a range of cognitive domains. On each test, subjects were classified as "impaired" if they performed 1 SD below age-based population norms. Total cognitive function scores were calculated by summing the number of tests on which individuals were classified as "impaired" (higher scores = greater impairment). Performance-based and self-reported functional limitations were assessed with the Short Physical Performance Battery (SPPB) and the Health Assessment Questionnaire (HAQ), respectively. Self-reported disability was measured with the Valued Life Activities (VLA) scale. Multiple regression analyses controlling for sex, race, education, cardiovascular comorbidity, disease duration, disease severity, and depression were conducted to identify whether cognitive impairment was independently associated with physical function difficulties. RESULTS: There were 122 subjects with mean (SD) age of 58.4 (± 10.8) years; 62% were female and 80% were white. In multivariate regression models, total cognitive function score was significantly associated with greater functional limitations (SPPB: β = -0.24, p = 0.014; HAQ: β = 0.24, p = 0.003) but not with disability (VLA: β = 0.10, p = 0.207). CONCLUSION:Cognitive impairment was significantly associated with greater functional limitations in patients with RA, suggesting that cognitive impairment may play a role in poor functional status in persons with RA.
Authors: M Bartolini; M Candela; M Brugni; L Catena; F Mari; G Pomponio; L Provinciali; G Danieli Journal: Clin Exp Rheumatol Date: 2002 Jul-Aug Impact factor: 4.473
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: Csaba Oláh; Zsófia Kardos; Mónika Andrejkovics; Enikő Szarka; Katalin Hodosi; Andrea Domján; Mariann Sepsi; Attila Sas; László Kostyál; Katalin Fazekas; Ágnes Flórián; Katalin Lukács; Ágnes Miksi; Zsuzsanna Baráth; György Kerekes; Márta Péntek; Attila Valikovics; László Tamási; Dániel Bereczki; Zoltán Szekanecz Journal: Rheumatol Int Date: 2019-09-25 Impact factor: 2.631
Authors: James S Andrews; Laura Trupin; Gabriela Schmajuk; Jennifer Barton; Mary Margaretten; Jinoos Yazdany; Edward H Yelin; Patricia P Katz Journal: Arthritis Care Res (Hoboken) Date: 2015-08 Impact factor: 4.794
Authors: Beatriz Caballero; Adrián Rubio-González; Yaiza Potes; Marta Martínez-Reig; Pedro Manuel Sánchez-Jurado; Luis Romero; Juan José Solano; Pedro Abizanda; Ana Coto-Montes Journal: Age (Dordr) Date: 2014-01-03
Authors: Li-Ming Wang; Qi Wu; Ryan A Kirk; Kevin P Horn; Ahmed H Ebada Salem; John M Hoffman; Jeffrey T Yap; Joshua A Sonnen; Rheal A Towner; Fernando A Bozza; Rosana S Rodrigues; Kathryn A Morton Journal: Am J Nucl Med Mol Imaging Date: 2018-04-25
Authors: Apostolos P Georgopoulos; Lisa M James; Adam F Carpenter; Brian E Engdahl; Arthur C Leuthold; Scott M Lewis Journal: Exp Brain Res Date: 2017-07-31 Impact factor: 1.972
Authors: James M Gwinnutt; Task Toyoda; Stephen Jeffs; Emma Flanagan; Jacqueline R Chipping; Jack R Dainty; Eneida Mioshi; Michael Hornberger; Alex MacGregor Journal: Rheumatol Adv Pract Date: 2021-06-27